Conference
Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369.
Authors
Clemons MJ; Cochrane B; Califaretti N; Chia SKL; Dent RA; Song X; Robidoux A; Pond GR; Parpla S; Pritchard KI
Volume
31
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2013
Name of conference
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
Chicago, IL
Conference start date
May 31, 2013
Conference end date
June 4, 2013
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X